0

Premature Ejaculation Treatment Market by Route of Administration, Drug Class, and Geography - Forecast and Analysis 2022-2026

  • Published: Jul 2022
  • Pages: 153
  • SKU: IRTNTR70413
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The premature ejaculation treatment market share is expected to increase by USD 1.26 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 9.06%.

This market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers market segmentation by route of administration (oral and topical), drug class (SSRIs, PDE5 inhibitors, amide anaesthetics, and others), and geography (North America, Europe, Asia, and the Rest of World (ROW)). The market report also offers information on several market vendors, including A. Menarini Industrie Farmaceutiche Riunite Srl, Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., ANI Pharmaceuticals Inc., Aytu BioPharma Inc., Bayer AG, Cipla Ltd., Eli Lilly and Co., Endurance RP Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Lupin Ltd., NeuroHealing Pharmaceuticals Inc., Novitium Pharma, Pfizer Inc., Plethora Solutions Ltd., Sandoz International GmbH, Solco Healthcare, and Teva Pharmaceutical Industries Ltd. among others.

What will the Premature Ejaculation Treatment Market Size be During the Forecast Period?

Premature Ejaculation Treatment Market Size

Download Report Sample to Unlock the Market Size for the Forecast Period and Other Important Statistics

 

Premature Ejaculation Treatment Market: Key Drivers, Trends, and Challenges

The high efficacy of off-label drugs is notably driving the market growth, although factors such as the availability of alternative treatment options may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the premature ejaculation treatment industry. The holistic analysis of the drivers will deduce end goals and refine marketing strategies to gain a competitive edge.

Key Market Driver

The high efficacy of off-label drugs is one of the major drivers impacting the market growth. The global market has witnessed an increase in the use of off-label drugs of different drug classes, such as SSRIs and PDE5 inhibitors, due to their effectiveness in the treatment of premature ejaculation. The treatment with off-label drugs belonging to SSRIs and PDE5 inhibitors has revolutionized the treatment approach. SSRIs, such as paroxetine, fluoxetine, and sertraline, are used to treat depression and mental health disorders and can cause delayed ejaculation in men. When the regulation of serotonin is disrupted in the central nervous system, ejaculation can be rehabilitated. Owing to such findings, SSRIs have been used in the management of premature ejaculation. In addition, some clinical studies have demonstrated that combining PDE5 inhibitors with SSRIs provides better results in the treatment of premature ejaculation than using SSRIs alone because the improved erection resulting from the PDE5 inhibitor inhibits ejaculation through the downregulation of the receptors involved in somatosensory latency times. The high efficacy of these drugs increases their demand among end-users, thereby contributing to the growth of the global market.

Key Market Trend

The advent of nanotechnology is one of the major trends influencing market growth. All of the currently used PDE-5 are orally administered. However, they have poor aqueous solubility, which results in low bioavailability and systemic side effects, such as facial flushing, headache, nasal congestion, and dyspepsia. Similarly, dapoxetine, a kind of SSRI, can reach a peak serum concentration in a short period. With the application of nanotechnology, researchers have explored new approaches to medicine delivery to promote efficacy and minimize the side effects of the currently available agents for premature ejaculation. For example, a study conducted by Han et al. demonstrated that nanoparticles represent a potential novel route for the topical delivery of erectogenic agents, which could improve the safety profile of the existing orally administered drugs by avoiding the effects of absorption and first-pass metabolism and would be less hazardous than injection. Therefore, nanotechnology has provided researchers with new approaches to develop a drug delivery system, which is expected to contribute to the growth of the market during the forecast period.

Key Market Challenge

The availability of alternative treatment options is one of the major challenges impeding the market growth. The growing number of premature ejaculation cases globally has led to an increase in the number of alternative treatment methods for the disease. Some of the alternate treatment methods are counselling, homeopathy, physiotherapy, psychotherapy, yoga, and herbal therapy. Psychotherapy and various behavioral therapies are also used to treat premature ejaculation. In addition to this, various behavioral therapies are useful in patients with premature ejaculation, which include masturbation before coitus (pre-coital masturbation), stop-start and squeeze techniques, the use of multiple condoms, and pelvic floor exercise. Controlled breathing exercises, Kegel exercises, and ayurvedic massage techniques are also recommended for people with premature ejaculation, and these treatment options have little or no side effects as compared with the mainstream premature ejaculation treatment drugs. The growing popularity of these alternative premature ejaculation treatment options has resulted in the diminished growth of authentic pharmacological therapies offered by various pharmaceutical companies, thus posing a threat to market growth.

This market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global premature ejaculation treatment market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the market during the forecast period.

Who are the Major Premature Ejaculation Treatment Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Absorption Pharmaceuticals LLC
  • Alembic Pharmaceuticals Inc.
  • Amneal Pharmaceuticals Inc.
  • ANI Pharmaceuticals Inc.
  • Aytu BioPharma Inc.
  • Bayer AG
  • Cipla Ltd.
  • Eli Lilly and Co.
  • Endurance RP Ltd.
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • Lupin Ltd.
  • NeuroHealing Pharmaceuticals Inc.
  • Novitium Pharma
  • Pfizer Inc.
  • Plethora Solutions Ltd.
  • Sandoz International GmbH
  • Solco Healthcare
  • Teva Pharmaceutical Industries Ltd.

 

This statistical study of the market encompasses successful business strategies deployed by the key vendors. The market is fragmented and the vendors are deploying growth strategies such as product differentiation to compete in the market.

Product Insights and News

  • pfizer.com - The company offers premature ejaculation treatments under the subsidiary Viagra.
  • pfizer.com - The company is engaged in the discovery, development, manufacturing, marketing, sales, and distribution of biopharmaceutical products worldwide.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Premature Ejaculation Treatment Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for the Premature Ejaculation Treatment Market?

Premature Ejaculation Treatment Market Share by Geography

For more insights on the market share of various regions Request PDF Sample now!

39% of the market’s growth will originate from North America during the forecast period. The US is the key market for premature ejaculation treatment in North America. Market growth in this region will be slower than the growth of the market in the European regions.

A significant rise in the number of premature ejaculation cases, owing to psychological strain and stress from an ever-changing lifestyle will facilitate the market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 had a negative impact on the regional market. The governments of countries such as the US, Canada, and Mexico imposed nationwide lockdowns and COVID-19-related restrictions to curb the spread of the disease. There was a decline in clinical visits of patients suffering from premature ejaculation disorders as they were particularly vulnerable to COVID-19. The delays in wellness visits and disruptions in the operations of hospitals and clinics owing to lockdowns resulted in a reduced diagnosis of the disorder, thereby reducing the regional demand for premature ejaculation treatment drugs.

What are the Revenue-generating Route of Administration Segments in the Premature Ejaculation Treatment Market?

Premature Ejaculation Treatment Market Share

To gain further insights on the market contribution of various segments Request a PDF Sample

The market share growth in the oral segment will be significant during the forecast period. The significant market share of the oral route segment can be attributed to the popularity and high preference for oral medication as the first line of treatment for premature ejaculation, owing to its ease of use and wide availability. These drugs are available in different forms, such as tablets, capsules, and liquids.

This report provides an accurate prediction of the contribution of all the segments to the growth of the market size and actionable market insights on post COVID-19 impact on each segment.

 

Premature Ejaculation Treatment Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 9.06%

Market growth 2022-2026

$ 1.26 billion

Market structure

Fragmented

YoY growth (%)

6.44

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 39%

Key consumer countries

US, Italy, UK, China, and India

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

A. Menarini Industrie Farmaceutiche Riunite Srl, Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., ANI Pharmaceuticals Inc., Aytu BioPharma Inc., Bayer AG, Cipla Ltd., Eli Lilly and Co., Endurance RP Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Lupin Ltd., NeuroHealing Pharmaceuticals Inc., Novitium Pharma, Pfizer Inc., Plethora Solutions Ltd., Sandoz International GmbH, Solco Healthcare, and Teva Pharmaceutical Industries Ltd. 

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Premature Ejaculation Treatment Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive market growth during the next five years
  • Precise estimation of the market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behaviour
  • The growth of the premature ejaculation treatment industry across North America, Europe, Asia, and the Rest of the World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 14: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 18: Five forces analysis - Comparison between 2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 19: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 20: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 21: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 22: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 23: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 24: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Route of Administration

    • 5.1 Market segments
      • Exhibit 25: Chart on Route of Administration - Market share 2021-2026 (%)
      • Exhibit 26: Data Table on Route of Administration - Market share 2021-2026 (%)
    • 5.2 Comparison by Route of Administration
      • Exhibit 27: Chart on Comparison by Route of Administration
      • Exhibit 28: Data Table on Comparison by Route of Administration
    • 5.3 Oral - Market size and forecast 2021-2026
      • Exhibit 29: Chart on Oral - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Data Table on Oral - Market size and forecast 2021-2026 ($ million)
      • Exhibit 31: Chart on Oral - Year-over-year growth 2021-2026 (%)
      • Exhibit 32: Data Table on Oral - Year-over-year growth 2021-2026 (%)
    • 5.4 Topical - Market size and forecast 2021-2026
      • Exhibit 33: Chart on Topical - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Data Table on Topical - Market size and forecast 2021-2026 ($ million)
      • Exhibit 35: Chart on Topical - Year-over-year growth 2021-2026 (%)
      • Exhibit 36: Data Table on Topical - Year-over-year growth 2021-2026 (%)
    • 5.5 Market opportunity by Route of Administration
      • Exhibit 37: Market opportunity by Route of Administration ($ million)

    6 Market Segmentation by Drug Class

    • 6.1 Market segments
      • Exhibit 38: Chart on Drug Class - Market share 2021-2026 (%)
      • Exhibit 39: Data Table on Drug Class - Market share 2021-2026 (%)
    • 6.2 Comparison by Drug Class
      • Exhibit 40: Chart on Comparison by Drug Class
      • Exhibit 41: Data Table on Comparison by Drug Class
    • 6.3 SSRIs - Market size and forecast 2021-2026
      • Exhibit 42: Chart on SSRIs - Market size and forecast 2021-2026 ($ million)
      • Exhibit 43: Data Table on SSRIs - Market size and forecast 2021-2026 ($ million)
      • Exhibit 44: Chart on SSRIs - Year-over-year growth 2021-2026 (%)
      • Exhibit 45: Data Table on SSRIs - Year-over-year growth 2021-2026 (%)
    • 6.4 PDE5 inhibitors - Market size and forecast 2021-2026
      • Exhibit 46: Chart on PDE5 inhibitors - Market size and forecast 2021-2026 ($ million)
      • Exhibit 47: Data Table on PDE5 inhibitors - Market size and forecast 2021-2026 ($ million)
      • Exhibit 48: Chart on PDE5 inhibitors - Year-over-year growth 2021-2026 (%)
      • Exhibit 49: Data Table on PDE5 inhibitors - Year-over-year growth 2021-2026 (%)
    • 6.5 Amide anesthetics - Market size and forecast 2021-2026
      • Exhibit 50: Chart on Amide anesthetics - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on Amide anesthetics - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on Amide anesthetics - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on Amide anesthetics - Year-over-year growth 2021-2026 (%)
    • 6.6 Others - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Others - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Others - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Others - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Others - Year-over-year growth 2021-2026 (%)
    • 6.7 Market opportunity by Drug Class
      • Exhibit 58: Market opportunity by Drug Class ($ million)

    7 Customer Landscape

    • 7.1 Customer landscape overview
      • Exhibit 59: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    8 Geographic Landscape

    • 8.1 Geographic segmentation
      • Exhibit 60: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 61: Data Table on Market share by geography 2021-2026 (%)
    • 8.2 Geographic comparison
      • Exhibit 62: Chart on Geographic comparison
      • Exhibit 63: Data Table on Geographic comparison
    • 8.3 North America - Market size and forecast 2021-2026
      • Exhibit 64: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 65: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 66: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 67: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 8.4 Europe - Market size and forecast 2021-2026
      • Exhibit 68: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 69: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 70: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 71: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 8.5 Asia - Market size and forecast 2021-2026
      • Exhibit 72: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 73: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 74: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 75: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 8.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 76: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 77: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 78: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 79: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 8.7 US - Market size and forecast 2021-2026
      • Exhibit 80: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 81: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 82: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 83: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 8.8 Italy - Market size and forecast 2021-2026
      • Exhibit 84: Chart on Italy - Market size and forecast 2021-2026 ($ million)
      • Exhibit 85: Data Table on Italy - Market size and forecast 2021-2026 ($ million)
      • Exhibit 86: Chart on Italy - Year-over-year growth 2021-2026 (%)
      • Exhibit 87: Data Table on Italy - Year-over-year growth 2021-2026 (%)
    • 8.9 China - Market size and forecast 2021-2026
      • Exhibit 88: Chart on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 89: Data Table on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 90: Chart on China - Year-over-year growth 2021-2026 (%)
      • Exhibit 91: Data Table on China - Year-over-year growth 2021-2026 (%)
    • 8.10 UK - Market size and forecast 2021-2026
      • Exhibit 92: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 93: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 94: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 95: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 8.11 India - Market size and forecast 2021-2026
      • Exhibit 96: Chart on India - Market size and forecast 2021-2026 ($ million)
      • Exhibit 97: Data Table on India - Market size and forecast 2021-2026 ($ million)
      • Exhibit 98: Chart on India - Year-over-year growth 2021-2026 (%)
      • Exhibit 99: Data Table on India - Year-over-year growth 2021-2026 (%)
    • 8.12 Market opportunity by geography
      • Exhibit 100: Market opportunity by geography ($ million)

    9 Drivers, Challenges, and Trends

    • 9.1 Market drivers
      • 9.2 Market challenges
        • 9.3 Impact of drivers and challenges
          • Exhibit 101: Impact of drivers and challenges in 2021 and 2026
        • 9.4 Market trends

          10 Vendor Landscape

          • 10.1 Overview
            • 10.2 Vendor landscape
              • Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
            • 10.3 Landscape disruption
              • Exhibit 103: Overview on factors of disruption
            • 10.4 Industry risks
              • Exhibit 104: Impact of key risks on business

            11 Vendor Analysis

            • 11.1 Vendors covered
              • Exhibit 105: Vendors covered
            • 11.2 Market positioning of vendors
              • Exhibit 106: Matrix on vendor position and classification
            • 11.3 Absorption Pharmaceuticals LLC
              • Exhibit 107: Absorption Pharmaceuticals LLC - Overview
              • Exhibit 108: Absorption Pharmaceuticals LLC - Product / Service
              • Exhibit 109: Absorption Pharmaceuticals LLC - Key offerings
            • 11.4 Alembic Pharmaceuticals Inc.
              • Exhibit 110: Alembic Pharmaceuticals Inc. - Overview
              • Exhibit 111: Alembic Pharmaceuticals Inc. - Product / Service
              • Exhibit 112: Alembic Pharmaceuticals Inc. - Key offerings
            • 11.5 Amneal Pharmaceuticals Inc.
              • Exhibit 113: Amneal Pharmaceuticals Inc. - Overview
              • Exhibit 114: Amneal Pharmaceuticals Inc. - Business segments
              • Exhibit 115: Amneal Pharmaceuticals Inc. - Key news
              • Exhibit 116: Amneal Pharmaceuticals Inc. - Key offerings
              • Exhibit 117: Amneal Pharmaceuticals Inc. - Segment focus
            • 11.6 Bayer AG
              • Exhibit 118: Bayer AG - Overview
              • Exhibit 119: Bayer AG - Business segments
              • Exhibit 120: Bayer AG - Key offerings
              • Exhibit 121: Bayer AG - Segment focus
            • 11.7 Cipla Ltd.
              • Exhibit 122: Cipla Ltd. - Overview
              • Exhibit 123: Cipla Ltd. - Business segments
              • Exhibit 124: Cipla Ltd. - Key news
              • Exhibit 125: Cipla Ltd. - Key offerings
              • Exhibit 126: Cipla Ltd. - Segment focus
            • 11.8 Eli Lilly and Co.
              • Exhibit 127: Eli Lilly and Co. - Overview
              • Exhibit 128: Eli Lilly and Co. - Product / Service
              • Exhibit 129: Eli Lilly and Co. - Key offerings
            • 11.9 Pfizer Inc.
              • Exhibit 130: Pfizer Inc. - Overview
              • Exhibit 131: Pfizer Inc. - Product / Service
              • Exhibit 132: Pfizer Inc. - Key news
              • Exhibit 133: Pfizer Inc. - Key offerings
            • 11.10 Sandoz International GmbH
              • Exhibit 134: Sandoz International GmbH - Overview
              • Exhibit 135: Sandoz International GmbH - Product / Service
              • Exhibit 136: Sandoz International GmbH - Key news
              • Exhibit 137: Sandoz International GmbH - Key offerings
            • 11.11 Solco Healthcare
              • Exhibit 138: Solco Healthcare - Overview
              • Exhibit 139: Solco Healthcare - Product / Service
              • Exhibit 140: Solco Healthcare - Key offerings
            • 11.12 Teva Pharmaceutical Industries Ltd.
              • Exhibit 141: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 142: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 143: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 144: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 145: Teva Pharmaceutical Industries Ltd. - Segment focus

            12 Appendix

            • 12.1 Scope of the report
              • 12.2 Inclusions and exclusions checklist
                • Exhibit 146: Inclusions checklist
                • Exhibit 147: Exclusions checklist
              • 12.3 Currency conversion rates for US$
                • Exhibit 148: Currency conversion rates for US$
              • 12.4 Research methodology
                • Exhibit 149: Research methodology
                • Exhibit 150: Validation techniques employed for market sizing
                • Exhibit 151: Information sources
              • 12.5 List of abbreviations
                • Exhibit 152: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Premature Ejaculation Treatment market growth will increase by $1290.65 million during 2020-2025.
              The premature ejaculation treatment market is expected to grow at a CAGR of 10.20% during 2020-2025.
              Technavio has segmented the premature ejaculation treatment market by other1 (Oral and Topical) ,other2 (SSRIs, PDE5 inhibitors, Amide anesthetics, and Others) , and geographic (North America, Europe, Asia, and ROW).
              Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Bayer AG, Eli Lilly and Co., InvaGen Pharmaceuticals Inc., Pfizer Inc., Sandoz AG, Solco Healthcare, Teva Pharmaceutical Industries Ltd. are a few of the key vendors in the premature ejaculation treatment market.
              North America will register the highest growth rate of 36.86% among the other regions. Therefore, the premature ejaculation treatment market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              • US
              • Germany
              • UK
              • France
              • Japan
              The key factors driving the premature ejaculation treatment market growth are:
              • High efficacy of off-label drugs
              • Advent of nanotechnology
              The premature ejaculation treatment market vendors should focus on grabbing business opportunities from the oral segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>